Matches in Wikidata for { <http://www.wikidata.org/entity/Q90841761> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- Q90841761 description "2020 թվականին հրատարակված գիտական հոդված" @default.
- Q90841761 description "article scientifique (publié 2020)" @default.
- Q90841761 description "articolo scientifico (pubblicato il 2020)" @default.
- Q90841761 description "artigo científico (publicado na 2020)" @default.
- Q90841761 description "artikull shkencor i botuar më 01 janar 2020" @default.
- Q90841761 description "artículo científico publicado en 2020" @default.
- Q90841761 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q90841761 description "im Januar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90841761 description "scientific article published on 01 January 2020" @default.
- Q90841761 description "wetenschappelijk artikel" @default.
- Q90841761 description "наукова стаття, опублікована 1 січня 2020" @default.
- Q90841761 description "научна статия" @default.
- Q90841761 name "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 name "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 name "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 type Item @default.
- Q90841761 label "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 label "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 label "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 prefLabel "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 prefLabel "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 prefLabel "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 P1433 Q90841761-5D2BE1FB-9B09-4C63-9A26-F47BC41455B8 @default.
- Q90841761 P1476 Q90841761-F56A3689-7B33-4E2B-BACD-281A41807D5E @default.
- Q90841761 P2093 Q90841761-0F6C4D4B-7873-4745-B86F-118CD39541FC @default.
- Q90841761 P2093 Q90841761-491EE802-8226-434B-8A3B-2530B7B65466 @default.
- Q90841761 P2093 Q90841761-7570072C-0CB6-4E20-850C-E2556E85F4C7 @default.
- Q90841761 P2093 Q90841761-8FC98A2C-3908-4F23-98A4-1632CB920A01 @default.
- Q90841761 P2093 Q90841761-91323102-2A59-4785-B2F3-A25D2040ADA4 @default.
- Q90841761 P2093 Q90841761-A8B105F6-B4B6-431B-9E49-DB5A1683A27C @default.
- Q90841761 P2093 Q90841761-B01E989E-75A5-4066-9CE9-413469A49545 @default.
- Q90841761 P2093 Q90841761-B7DA4593-553A-4FDD-8741-90FE4B93F71B @default.
- Q90841761 P2093 Q90841761-DF5FC5DC-08BB-45D7-9EEE-1EEF82295709 @default.
- Q90841761 P2093 Q90841761-F3A70DD2-A467-4888-9B53-43AACE8F5C58 @default.
- Q90841761 P2093 Q90841761-FBE66224-80EA-481D-96A7-504F7658873F @default.
- Q90841761 P275 Q90841761-aedddf80-5eb2-4cd4-afcf-d79d81a77582 @default.
- Q90841761 P304 Q90841761-22510993-6040-4E0A-9ADD-FEDDE6D1BA33 @default.
- Q90841761 P31 Q90841761-C0BEF254-9F7E-45AD-9580-4E2FC1EF3EBE @default.
- Q90841761 P356 Q90841761-9C9F2A3C-7F81-4A59-9190-A3969F918A9C @default.
- Q90841761 P433 Q90841761-456BFC18-EEFF-4A4A-94F4-B48D59F98F38 @default.
- Q90841761 P478 Q90841761-FED99236-AE69-475E-87E9-F50BE042D17A @default.
- Q90841761 P50 Q90841761-D19B9773-1540-46B7-8133-5F2024844664 @default.
- Q90841761 P577 Q90841761-036F8F61-B60A-4C4F-B8E6-C9C169A9331F @default.
- Q90841761 P6216 Q90841761-fdc9819c-2773-4ace-9e55-d1d77b4f3e5d @default.
- Q90841761 P698 Q90841761-326CA292-EDBE-4A5D-BFB4-A64F3C55E4F6 @default.
- Q90841761 P932 Q90841761-AEE9344A-A270-4B55-A6AA-F8BB54646C70 @default.
- Q90841761 P356 HYZ132 @default.
- Q90841761 P698 31633185 @default.
- Q90841761 P1433 Q2231629 @default.
- Q90841761 P1476 "Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up" @default.
- Q90841761 P2093 "Hirotsugu Uemura" @default.
- Q90841761 P2093 "Masahiro Yao" @default.
- Q90841761 P2093 "Mototsugu Oya" @default.
- Q90841761 P2093 "Robert J Motzer" @default.
- Q90841761 P2093 "Takamitsu Inoue" @default.
- Q90841761 P2093 "Takayuki Sugiyama" @default.
- Q90841761 P2093 "Tsunenori Kondo" @default.
- Q90841761 P2093 "Wataru Obara" @default.
- Q90841761 P2093 "Yasuhisa Fujii" @default.
- Q90841761 P2093 "Yoshiaki Wakumoto" @default.
- Q90841761 P2093 "Yoshihiko Tomita" @default.
- Q90841761 P275 Q34179348 @default.
- Q90841761 P304 "12-19" @default.
- Q90841761 P31 Q13442814 @default.
- Q90841761 P356 "10.1093/JJCO/HYZ132" @default.
- Q90841761 P433 "1" @default.
- Q90841761 P478 "50" @default.
- Q90841761 P50 Q61873026 @default.
- Q90841761 P577 "2020-01-01T00:00:00Z" @default.
- Q90841761 P6216 Q50423863 @default.
- Q90841761 P698 "31633185" @default.
- Q90841761 P932 "6978670" @default.